Preclinical Targeting of the PGRMC1-CK2 Axis with Silmitasertib: A Potential Strategy for Lung Adenocarcinoma Therapy

Abstract

Progesterone receptor membrane component 1 (PGRMC1) is a pleiotropic protein over-expressed in lung adenocarcinoma (LUAD). The precise molecular mechanisms underlying the signature motif of Casein kinase (CK2) presence in PGRMC1 and their role in LUAD remain unclear. X-ray crystallographic structure for CK2 and PGRMC1 from the PubChem database was obtained and subjected to protein-protein interaction (PPI) analysis to identify their interactions. In addition, the CK2 inhibitor – Silmitasertib was also utilised to understand the interaction between PGRMC1-CK2. The PPI complex (PGRMC1-CK2) and the PPI-ligand interaction analysis and their Molecular Dynamics (MD) studies revealed the stability of their interactions and critical amino acid contacts within the 5Ǻ vicinity of the CK2 signature motif "T/S-x-x-E/D". Moreover, in-vitro colony formation assay, migration assay, and gene expression analysis using quantitative Real-time PCR revealed that Silmitasertib (IC₅₀–2.5 μM) was highly influential in suppressing the PGRMC1-CK2 expression axis. In conclusion, our study infers that PGRMC1-CK-2 axis inhibition could be a potential therapeutic option to limit the promotion and progression of lung cancer.

Keywords

CK2 signature motif - lung cancer - health and disease - bioinformatics - in-vitro

• References

• 1 Solairaja S, Ramalingam S, Dunna NR. et al Progesterone receptor membrane component 1 and its accomplice: emerging therapeutic targets in lung cancer. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders) 2022; 22: 601-611
• 2 Pru JK. Pleiotropic actions of PGRMC proteins in cancer. Endocrinology. 2022; 163: bqac078
• 3 Cahill MA, Neubauer H. PGRMC proteins are coming of age: a special issue on the role of PGRMC1 and PGRMC2 in metabolism and cancer biology. Cancers. 2021; 13: 512
• 4 Grygier P, Pustelny K, Nowak J. et al. Silmitasertib (CX-4945), a clinically used CK2-kinase inhibitor with additional effects on GSK3β and DYRK1A kinases: a structural perspective. Journal of Medicinal Chemistry 2023; 66: 4009-4024
• 5 Gowda C, Sachdev M, Muthusami S. et al. kinase II (CK2) as a therapeutic target for hematological malignancies. Current Pharmaceutical Design 2017; 23: 95-107
• 6 Purzner T, Purzner J, Buckstaff T. et al. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Science signaling 2018; 11: eaau5147
• 7 Pagni M, Ioannidis V, Cerutti L. et al. MyHits: improvements to an interactive resource for analyzing protein sequences. Nucleic acids research 2007; 35: W433-W437
• 8 De Castro E, Sigrist CJ, Gattiker A. et al. ScanProsite: detection of PROSITE signature matches and ProRule-associated functional and structural residues in proteins. Nucleic acids research 2006; 34: W362-W365
• 9 Ashkenazy H, Abadi S, Martz E. et al. ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic acids research 2016; 44: W344-W350
• 10 Yan Y, Huang SY. Modeling protein–protein or protein–DNA/RNA complexes using the HDOCK webserver. Protein Structure Prediction 2020; 217-229
• 11 Halder D, Das S, Joseph A. et al. Molecular docking and dynamics approach to in silico drug repurposing for inflammatory bowels disease by targeting TNF alpha. Journal of Biomolecular Structure and Dynamics 2023; 41: 3462-3475
• 12 Ivánczi M, Balogh B, Kis L. et al. Molecular Dynamics Simulations of Drug-Conjugated Cell-Penetrating Peptides. Pharmaceuticals. 2023; 16: 1251
• 13 Lazer LM, Sadhasivam B, Palaniyandi K. et al. Chitosan-based nano-formulation enhances the anticancer efficacy of hesperetin. International journal of biological macromolecules 2018; 107: 1988-1998
• 14 Cahill MA, Jazayeri JA, Kovacevic Z. et al. PGRMC1 regulation by phosphorylation: potential new insights in controlling biological activity!. Oncotarget 2016; 7: 50822